Uniquity Bio

A clinical-stage drug development company focused on immunology and inflammation.

In May 2024, the Blackstone Life Sciences portfolio company Uniquity Bio emerged from stealth with an FDA acceptance of its Phase II investigational new drug (IND) application for solrikitug, a monoclonal antibody targeting TSLP, and up to $300 million in capital from Blackstone to advance the asset in multiple indications.